Listen now
Key takeaways
- Kevin Saem, founder of Zaparus, developed a market intelligence platform specifically for MedTech after identifying a five-year lag in the industry compared to pharma and biotech.
- Zaparus uses machine learning to analyze public data and identify critical sales signals, enabling MedTech service providers to proactively engage with potential clients at optimal times.
- The platform aims to transition MedTech sales from reactive, traditional methods to a data-driven approach, improving efficiency and effectiveness.
- Stricter regulations, such as the EU MDR and IVDR, can attract investment by creating a more stable and predictable market environment.
- Prioritizing cybersecurity and commercial strategy from the outset is crucial for MedTech startups to secure funding and navigate increasing scrutiny from regulators like the FDA.
- The MedTech market is consolidating, making scalable processes and proactive strategies essential for smaller companies to thrive and attract acquisition.
- Early adoption of advanced tools and a proactive commercial strategy are vital for MedTech startups to ensure sustainable growth and avoid the pitfalls of a limited financial runway.
In the MedTech space, how can you leverage market intelligence and machine learning for business development and sales enablement?
In this episode, Christian and Trevor talk with Kevin Saem about how market intelligence and cybersecurity intersect in the MedTech space. They unpack how AI and data-driven insights are transforming sales enablement, investor confidence, and device security. They also discuss regulation delays, startup runway challenges, and the growing need for proactive cybersecurity.
Kevin Saem founded Zapyrus, a SaaS platform that helps MedTech service providers supercharge sales through AI-driven market intelligence.
Key points:
(04:20) Why MedTech lags five years behind pharma in regulation and sales sophistication.
(06:30) How Zapyrus uses machine learning to identify market signals and automate sales research.
(08:45) Why regulatory clarity in Europe is fueling more MedTech investment than in the U.S.
(12:00) How AI and connected devices are making cybersecurity a top concern for investors.
(19:07) What the Illumina case and AI therapy failures reveal about industry accountability.
(26:30) How MedTech founders can self-regulate.
(32:40) When companies should start building scalable sales systems.
Learn about Zapyrus, a sales system for MedTech service providers: https://welcome.zapyrus.com/
Notable quotes
“MedTech, from a regulatory sophistication, sales sophistication, company sophistication, has historically been a minimum of five years behind life sciences like pharma and biotech.”
“What was born out of that were traditional databases, basically digitized curation of information in a platform. Then you saw the emergence of selling contacts, which was such a taboo.”
“Zaparus was born out of COVID, and we've been scaling up ever since.”
“I came from the research world in the early days, so a technical space, right? My PhD was in chemistry, technically, but translational chemistry.”
Frequently asked questions
Bring this work to your device
Need help with penetration testing?
Blue Goat Cyber delivers medical device penetration testing for medical device manufacturers - from threat modeling to FDA-ready reports.
Medical Device Penetration TestingMore on Penetration Testing
Keep listening
-
Episode 66
Vibe Coding Security Risks & Malicious Injection with Jake Rodriguez of Triangle Tech
With Jake Rodriguez
-
Episode 60
How to Move Stakeholders from Awareness to Sustained Adoption Without Friction
With MedTech leader
-
Episode 42
What Is A Medical Cyber Device?
-
Episode 36
When Medical Device Cybersecurity Becomes a Crime